Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoVAX in Stage II colon cancer
NCT02448173Phase 3Not yet recruiting
- Sponsor
- Vaccinogen Inc.
- Start
- Aug 2026
- Primary completion
- Aug 2031
- Modality
- Vaccines & Immunotherapeutics, Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 3 trial of OncoVAX in colon cancer, sponsored by Vaccinogen Inc.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
OncoVAX
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02448173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448173.